Nisa Investment Advisors Reduces Neurocrine Biosciences Stake

Institutional investor sells over 80% of shares in biotech firm

Apr. 5, 2026 at 9:06am

Got story updates? Submit your updates here. ›

Nisa Investment Advisors LLC reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% during the 4th quarter, according to the company's recent 13F filing with the SEC. The institutional investor now owns 5,201 shares of the company's stock, down from 27,146 shares previously.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The significant reduction in Nisa Investment Advisors' stake could signal a shift in investor sentiment or portfolio strategy regarding the company's future prospects.

The details

Nisa Investment Advisors sold 21,945 shares of Neurocrine Biosciences during the fourth quarter, reducing its total holdings to 5,201 shares worth approximately $738,000. The institutional investor cited unspecified reasons for the portfolio adjustment, which came amid broader market volatility and uncertainty surrounding the biotech sector.

  • Nisa Investment Advisors reduced its Neurocrine Biosciences stake during the 4th quarter of 2025.

The players

Nisa Investment Advisors LLC

An institutional investment firm that manages a portfolio of stocks, bonds, and other assets on behalf of its clients.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders, including tardive dyskinesia and Parkinson's disease.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Nisa Investment Advisors' stake in Neurocrine Biosciences could signal broader uncertainty or shifting sentiment around the biotech firm's future prospects, though the specific reasons remain unclear. This development highlights the volatility and unpredictability that can characterize the biotech investment landscape.